Abstract: Objective To investigate the efficacy of transcatheter arterial chemoembolization （TACE） and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma（HCC） at special sites. Methods Seventy-two patients with HCC,out of them,thirty-six with HCC at special sites （observation group）,were enrolled in our hospital between January 2012 and January 2015,and all of them received TACE and ultrasound-guided microwave ablation seven days after. The patients with HCC in the two groups were followed- up for two years after the treatment was completed. The survival was analyzed by Kaplan-Meier methods. Results The rates of complete response,partial response,disease stable and disease progress in the observation group were 44.4%,25.0%,19.5% and 11.1%,not significantly different as compared to 47.2%,27.8%,16.7% and 8.3% in the control（P>0.05）;serum AFP negativity rate in the observation group was 84.4%,not significantly different as compared to 83.9% in the control（P>0.05）;the survival rates at 6 m,1 a,18 m and 2 a were 94.4%,88.9%,69.4% and 44.4%,not significantly different as compared to 100.0%,91.7%,75.0% and 47.2%,respectively（P>0.05）;the incidences of right hypochondriac region pain,fever,anorexia and abnormal liver function tests after operations in the two groups were not significantly different（P>0.05）. Conclusion The application of hepatic artery chemoembolization combined with ultrasound-guided microwave ablation in the treatment of patients with HCC at special sites might have the same clinical efficacy as usual,but we still remind clinicians taking much more attention to those patients during the process.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Microwave ablation, Special sites, Clinical efficacy